Fulgent Genetics, INC Form 4 insider transactions

Fulgent Genetics CEO Ming Hsieh disposed of 2,115 shares of common stock to cover tax withholding obligations related to RSU vesting.

Fulgent Genetics' CFO, Paul Kim, disposed of 670 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 548 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Fulgent Genetics CEO Ming Hsieh reported a disposition of shares to cover tax obligations from vested restricted stock units.

Fulgent Genetics' CFO and Treasurer, Paul Kim, reported the disposition of 2,743 shares of common stock valued at $18.37 per share to cover tax withholding obligations from restricted stock unit vesting.

Fulgent Genetics, Inc.'s President and COO, Jian Xie, reported the disposition of 4,352 shares of common stock at $18.37 per share to cover tax withholding obligations related to restricted stock unit vesting.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, reported a future disposition of 1,642 common shares at $18.37 each to cover tax obligations related to restricted stock unit vesting.

The Ming Hsieh Trust, associated with Fulgent Genetics CEO Ming Hsieh, has paid over $16.4 million to cancel a prepaid variable forward agreement, regaining control of 800,000 shares of Fulgent Genetics common stock.

Fulgent Genetics CFO and Treasurer Paul Kim reported the disposition of 1,131 shares of common stock on June 1, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 754 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Jian Xie, President and COO of Fulgent Genetics, Inc., reported the sale of 1,135 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Jian Xie, President and COO of Fulgent Genetics, Inc., sold 1,873 shares of common stock on May 27, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported the disposition of 1,837 shares of common stock across two transactions in late May 2025, primarily to satisfy tax withholding obligations related to vested restricted stock units.

Fulgent Genetics, Inc. CEO Ming Hsieh reported the disposition of 5,060 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, reported the sale of 1,039 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Director Linda Marsh reported the acquisition of restricted stock units and the disposal of common stock in Fulgent Genetics, Inc.

Director Michael Nohaile reports acquisition and disposal of Fulgent Genetics stock and stock options.

Director Regina E. Groves acquired 8,982 shares of Fulgent Genetics, Inc. on May 15, 2025, through restricted stock units.

Fulgent Genetics CEO Ming Hsieh reports disposition of shares to cover tax obligations and details beneficial ownership through trusts and minor accounts.

Chief Scientific Officer of Fulgent Genetics, Gao Hanlin, reports disposition of shares to cover tax obligations.

Jian Xie, President and COO of Fulgent Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

CFO of Fulgent Genetics, Paul Kim, reports disposition of shares to cover tax obligations from vesting restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports a transaction involving common stock to cover tax obligations.

Fulgent Genetics' CFO and Treasurer, Paul Kim, purchased 100,000 shares of the company's common stock at an average price of $15.9647 on March 5, 2025.

Jian Xie, President and COO of Fulgent Genetics, reports a transaction involving common stock related to tax withholding obligations and holdings in a family trust.

Jian Xie, President and COO of Fulgent Genetics, files an amended SEC Form 4 to correct transaction dates related to tax withholding obligations on vested restricted stock units.

CFO and Treasurer of Fulgent Genetics, Paul Kim, reports disposition of shares to cover tax obligations arising from vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports disposition of shares to cover tax obligations.

CFO and Treasurer of Fulgent Genetics, Paul Kim, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units (RSUs), with shares withheld to cover tax obligations.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units, along with shares withheld for tax obligations.